NO20081045L - Forbindelser og fremgangsmater for behandling av cancer - Google Patents
Forbindelser og fremgangsmater for behandling av cancerInfo
- Publication number
- NO20081045L NO20081045L NO20081045A NO20081045A NO20081045L NO 20081045 L NO20081045 L NO 20081045L NO 20081045 A NO20081045 A NO 20081045A NO 20081045 A NO20081045 A NO 20081045A NO 20081045 L NO20081045 L NO 20081045L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- methods
- treating cancer
- leukemia
- potent
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001495 arsenic compounds Chemical class 0.000 abstract 1
- 210000000601 blood cell Anatomy 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 229940093920 gynecological arsenic compound Drugs 0.000 abstract 1
- 230000002489 hematologic effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/285—Arsenic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/66—Arsenic compounds
- C07F9/70—Organo-arsenic compounds
- C07F9/72—Aliphatic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70416305P | 2005-07-29 | 2005-07-29 | |
| PCT/US2006/029835 WO2007027344A2 (en) | 2005-07-29 | 2006-07-28 | Compounds and methods for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20081045L true NO20081045L (no) | 2008-04-25 |
Family
ID=37809342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20081045A NO20081045L (no) | 2005-07-29 | 2008-02-28 | Forbindelser og fremgangsmater for behandling av cancer |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US7968738B2 (enExample) |
| EP (2) | EP2394702B1 (enExample) |
| JP (1) | JP4994374B2 (enExample) |
| AU (1) | AU2006285329B2 (enExample) |
| CA (1) | CA2617049A1 (enExample) |
| ES (2) | ES2532666T3 (enExample) |
| NO (1) | NO20081045L (enExample) |
| WO (1) | WO2007027344A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2394702B1 (en) | 2005-07-29 | 2014-12-31 | Ziopharm Oncology, Inc. | Compounds and methods for the treatment of cancer |
| TW200829261A (en) | 2006-09-29 | 2008-07-16 | Ziopharm Oncology Inc | Method for controlling angiogenesis in animals |
| US8252773B2 (en) * | 2007-11-02 | 2012-08-28 | Ziopharm Oncology, Inc. | Combination therapy with organic arsenicals |
| WO2009075870A1 (en) * | 2007-12-12 | 2009-06-18 | Ziopharm Oncology, Inc. | Compounds and methods for the treatment of cancer |
| NZ591181A (en) * | 2008-08-20 | 2012-09-28 | Ziopharm Oncology Inc | Organoarsenic compounds and methods for the treatment of cancer |
| CN104768875A (zh) | 2012-09-20 | 2015-07-08 | 于伽·纳拉扬·本德勒 | 纳米三氧化二砷的生物合成方法及其在治疗包括癌症的疾病中的用途 |
| US20160304546A1 (en) * | 2013-12-05 | 2016-10-20 | Solasia Pharma K.K. | Compounds and methods for the treatment of cancer |
| CN107530476A (zh) * | 2015-03-12 | 2018-01-02 | 般财团法人化学及血清疗法研究所 | 使用脱细胞化组织的抗粘连材料和代用生物膜 |
| CN107167433A (zh) * | 2016-03-07 | 2017-09-15 | 天津国际生物医药联合研究院 | 一种检测氯二甲基砷的方法 |
| WO2019220961A1 (ja) * | 2018-05-18 | 2019-11-21 | ソレイジア・ファーマ株式会社 | ダリナパルシンのアルカリ金属塩及び／又は無機酸付加塩の結晶型及びその製剤 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277819B1 (en) * | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
| DE69840057D1 (de) | 1997-10-15 | 2008-11-06 | Polarx Biopharmaceuticals Inc | Pharmazeutische Zusammensetzungen enthaltend Arsentrioxid zur Behandlung von Krebs des zentralen Nervensystems |
| EP1964557B1 (en) | 1997-11-10 | 2013-01-02 | Memorial Sloan-Kettering Cancer Center | Process for producing arsenic trioxide formulations |
| WO1999029336A1 (en) * | 1997-12-05 | 1999-06-17 | Eli Lilly And Company | Glp-1 formulations |
| CN1233476A (zh) | 1998-04-24 | 1999-11-03 | 陆道培 | 治疗急性白血病的药物及其制备方法 |
| SE9802080D0 (sv) * | 1998-06-11 | 1998-06-11 | Hellstroem | Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein |
| EP1002537A1 (en) | 1998-10-30 | 2000-05-24 | Assistance Publique, Hopitaux De Paris | Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma |
| US6191123B1 (en) | 1999-03-19 | 2001-02-20 | Parker Hughes Institute | Organic-arsenic compounds |
| US7022315B2 (en) | 2000-04-26 | 2006-04-04 | Oregon Health & Science University | Administration of a thiol-based chemoprotectant compound |
| EP2420229A1 (en) * | 2002-01-07 | 2012-02-22 | Board Of Regents, University Of Texas System | S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer |
| TW201440760A (zh) * | 2004-07-16 | 2014-11-01 | Texas A & M Univ Sys | 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物 |
| EP2394702B1 (en) | 2005-07-29 | 2014-12-31 | Ziopharm Oncology, Inc. | Compounds and methods for the treatment of cancer |
| US8252773B2 (en) * | 2007-11-02 | 2012-08-28 | Ziopharm Oncology, Inc. | Combination therapy with organic arsenicals |
-
2006
- 2006-07-28 EP EP11180330.0A patent/EP2394702B1/en not_active Not-in-force
- 2006-07-28 ES ES11180330.0T patent/ES2532666T3/es active Active
- 2006-07-28 EP EP06824793.1A patent/EP1919564B1/en active Active
- 2006-07-28 US US11/495,172 patent/US7968738B2/en active Active
- 2006-07-28 AU AU2006285329A patent/AU2006285329B2/en not_active Ceased
- 2006-07-28 WO PCT/US2006/029835 patent/WO2007027344A2/en not_active Ceased
- 2006-07-28 JP JP2008524273A patent/JP4994374B2/ja active Active
- 2006-07-28 ES ES06824793T patent/ES2531159T3/es active Active
- 2006-07-28 CA CA002617049A patent/CA2617049A1/en not_active Abandoned
-
2008
- 2008-02-28 NO NO20081045A patent/NO20081045L/no not_active Application Discontinuation
-
2011
- 2011-06-01 US US13/150,516 patent/US8334398B2/en active Active
-
2012
- 2012-11-14 US US13/676,929 patent/US8865764B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP1919564B1 (en) | 2014-11-26 |
| US20070183972A1 (en) | 2007-08-09 |
| US8334398B2 (en) | 2012-12-18 |
| ES2532666T3 (es) | 2015-03-30 |
| US20120022229A1 (en) | 2012-01-26 |
| AU2006285329A2 (en) | 2008-08-14 |
| US7968738B2 (en) | 2011-06-28 |
| US8865764B2 (en) | 2014-10-21 |
| HK1117780A1 (en) | 2009-01-23 |
| EP2394702A1 (en) | 2011-12-14 |
| EP2394702B1 (en) | 2014-12-31 |
| AU2006285329B2 (en) | 2012-10-04 |
| US20130142730A1 (en) | 2013-06-06 |
| AU2006285329A1 (en) | 2007-03-08 |
| WO2007027344A2 (en) | 2007-03-08 |
| WO2007027344A3 (en) | 2007-12-21 |
| EP1919564A2 (en) | 2008-05-14 |
| JP2009502971A (ja) | 2009-01-29 |
| HK1164767A1 (en) | 2012-09-28 |
| CA2617049A1 (en) | 2007-03-08 |
| ES2531159T3 (es) | 2015-03-11 |
| JP4994374B2 (ja) | 2012-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20081045L (no) | Forbindelser og fremgangsmater for behandling av cancer | |
| TW200616615A (en) | Compounds and methods for the treatment of cancer | |
| WO2011098262A3 (en) | P19arf, hmga2 and mdm2 for use in the diagnosis and treatment of aberrant cell growth | |
| IL186104A0 (en) | Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer | |
| SG151267A1 (en) | Carboline derivatives useful in the inhibition of angiogenesis | |
| NO20075918L (no) | Substituerte pyrrolo-pyridiner, forbindelser inneholdende disse, fremgangsmate for deres fremstilling og anvendelse derav | |
| ECSP088536A (es) | DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR | |
| NO2017019I2 (no) | Enzalutamid eller et farmasøytisk akseptabelt salt derav | |
| NZ597075A (en) | 1, 2, 4-thiazolidin-3-one derivatives as AMP-activated protein kinase (AMPK) agonists for treating cancer | |
| WO2006058014A3 (en) | Harnessing network biology to improve drug discovery | |
| UA98629C2 (ru) | Соединения и способ модуляции киназ | |
| MY139942A (en) | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | |
| RU2711869C3 (ru) | Имидазопирролопиразиновые производные, полезные для лечения заболеваний, вызванных аномальной активностью протеинкиназ Jak1, Jak3 или Syk | |
| WO2005113747A3 (de) | Multizelluläre gewebe- und organkultursysteme | |
| BRPI0607306A2 (pt) | derivados de quinoxalina como agentes anti-tumor | |
| UY29826A1 (es) | Derivados de pirimidina, sales farmaceuticamente aceptables, esteres de los mismos hidrolisables in vivo, procesos de preparacion y aplicaciones | |
| NL2000375A1 (nl) | Pyrimidinederivaten voor de behandeling van abnormale celgroei. | |
| MX2009003778A (es) | Alimentacion a largo plazo para paciente de cancer. | |
| UY31305A1 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen. | |
| DE602005019762D1 (de) | Medizinisches Instrument zum Manipulieren, insbesondere zum Zurückziehen des Gewebes oder des Organes. | |
| WO2010028373A3 (en) | Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients | |
| WO2006009765A3 (en) | Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells | |
| WO2007118751A3 (de) | Verfahren zur veränderung des atp-adp-verhältnisses in zellen | |
| ATE245655T1 (de) | Organische-arsenverbindungen | |
| TW200731991A (en) | Lipophilic di(anticancer drug) compounds, compositions and related methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |